2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 957

International Patient and Physician Consensus on Psoriatic Arthritis Outcomes for Clinical Trials
Abstract Number: 958

Safety and Efficacy of ABT-122, a TNF and IL-17–Targeted Dual Variable Domain (DVD)–Ig™, in Psoriatic Arthritis Patients with Inadequate Response to Methotrexate: Results from a Phase 2 Trial
Abstract Number: 959

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52 Week Results from a Phase 3 Study
Abstract Number: 960

Ultrasonographic Improvement of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated with Ustekinumab for Chronic Plaque Psoriasis: A 52-Week, Prospective, Open Label, Controlled Cohort Study
Abstract Number: 961

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis through 3 Years: Efficacy and Safety Results from a Phase 3 Trial
Abstract Number: 962

No Increased Risk of Inflammatory Bowel Disease Among Secukinumab-Treated Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis: Data from 14 Phase 2 and Phase 3 Clinical Studies
Abstract Number: 963

Treatment of Homocysteine Improves Urine Protein/Cr Ratio in SLE
Abstract Number: 964

Tubulointerstitial Damage Is an Independent Predictor of End Stage Renal Disease in Lupus Nephritis Patients with Mild to Moderate Renal Impairment
Abstract Number: 965

Clinical and Serologic Variables Associated with Renal Response Among Lupus Nephritis Phase III Trial Patients Treated with Standard of Care Immunosuppression
Abstract Number: 966

Renal Activity in Lupus (RAIL) Urinary Biomarkers Predict Treatment Response
Abstract Number: 967

Using a Hazard Index Tool Based on Short Term Renal Parameters to Predict Long Term Outcomes in Lupus Nephritis: A Novel Way to Assess New Therapies
Abstract Number: 968

Urinary Soluble CD163, an M2 Macrophage Marker, Reflects the Renal Disease Activity in Lupus Nephritis: A Cross Sectional and Longitudinal Assessment
Abstract Number: 969

Safety and Efficacy of Subcutaneous Tocilizumab in Early Systemic Sclerosis: Results from the Open-Label Period of a Phase 2 Randomized, Controlled Trial
Abstract Number: 970

The Serotonin Receptor 2 Inhibitor Terguride Has Beneficial Effects on Skin Fibrosis: Results from a Phase 2 Proof of Concept Study
Abstract Number: 971

Reliability and Minimal Clinically Important Differences (MCID) of Forced Vital Capacity: Post-Hoc Analyses from the Scleroderma Lung Studies (SLS-I and II)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].